Cargando…

Promising genes and variants to reduce chemotherapy adverse effects in acute lymphoblastic leukemia

Almost two decades ago, the sequencing of the human genome and high throughput technologies came to revolutionize the clinical and therapeutic approaches of patients with complex human diseases. In acute lymphoblastic leukemia (ALL), the most frequent childhood malignancy, these technologies have en...

Descripción completa

Detalles Bibliográficos
Autores principales: Bárcenas-López, Diego Alberto, Mendiola-Soto, Diana Karen, Núñez-Enríquez, Juan Carlos, Mejía-Aranguré, Juan Manuel, Hidalgo-Miranda, Alfredo, Jiménez-Morales, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720095/
https://www.ncbi.nlm.nih.gov/pubmed/33290991
http://dx.doi.org/10.1016/j.tranon.2020.100978
_version_ 1783619798538649600
author Bárcenas-López, Diego Alberto
Mendiola-Soto, Diana Karen
Núñez-Enríquez, Juan Carlos
Mejía-Aranguré, Juan Manuel
Hidalgo-Miranda, Alfredo
Jiménez-Morales, Silvia
author_facet Bárcenas-López, Diego Alberto
Mendiola-Soto, Diana Karen
Núñez-Enríquez, Juan Carlos
Mejía-Aranguré, Juan Manuel
Hidalgo-Miranda, Alfredo
Jiménez-Morales, Silvia
author_sort Bárcenas-López, Diego Alberto
collection PubMed
description Almost two decades ago, the sequencing of the human genome and high throughput technologies came to revolutionize the clinical and therapeutic approaches of patients with complex human diseases. In acute lymphoblastic leukemia (ALL), the most frequent childhood malignancy, these technologies have enabled to characterize the genomic landscape of the disease and have significantly improved the survival rates of ALL patients. Despite this, adverse reactions from treatment such as toxicity, drug resistance and secondary tumors formation are still serious consequences of chemotherapy, and the main obstacles to reduce ALL-related mortality. It is well known that germline variants and somatic mutations in genes involved in drug metabolism impact the efficacy of drugs used in oncohematological diseases therapy. So far, a broader spectrum of clinically actionable alterations that seems to be crucial for the progression and treatment response have been identified. Although these results are promising, it is necessary to put this knowledge into the clinics to help physician make medical decisions and generate an impact in patients’ health. This review summarizes the gene variants and clinically actionable mutations that modify the efficacy of antileukemic drugs. Therefore, knowing their genetic status before treatment is critical to reduce severe adverse effects, toxicities and life-threatening consequences in ALL patients.
format Online
Article
Text
id pubmed-7720095
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Neoplasia Press
record_format MEDLINE/PubMed
spelling pubmed-77200952020-12-15 Promising genes and variants to reduce chemotherapy adverse effects in acute lymphoblastic leukemia Bárcenas-López, Diego Alberto Mendiola-Soto, Diana Karen Núñez-Enríquez, Juan Carlos Mejía-Aranguré, Juan Manuel Hidalgo-Miranda, Alfredo Jiménez-Morales, Silvia Transl Oncol Review article Almost two decades ago, the sequencing of the human genome and high throughput technologies came to revolutionize the clinical and therapeutic approaches of patients with complex human diseases. In acute lymphoblastic leukemia (ALL), the most frequent childhood malignancy, these technologies have enabled to characterize the genomic landscape of the disease and have significantly improved the survival rates of ALL patients. Despite this, adverse reactions from treatment such as toxicity, drug resistance and secondary tumors formation are still serious consequences of chemotherapy, and the main obstacles to reduce ALL-related mortality. It is well known that germline variants and somatic mutations in genes involved in drug metabolism impact the efficacy of drugs used in oncohematological diseases therapy. So far, a broader spectrum of clinically actionable alterations that seems to be crucial for the progression and treatment response have been identified. Although these results are promising, it is necessary to put this knowledge into the clinics to help physician make medical decisions and generate an impact in patients’ health. This review summarizes the gene variants and clinically actionable mutations that modify the efficacy of antileukemic drugs. Therefore, knowing their genetic status before treatment is critical to reduce severe adverse effects, toxicities and life-threatening consequences in ALL patients. Neoplasia Press 2020-12-05 /pmc/articles/PMC7720095/ /pubmed/33290991 http://dx.doi.org/10.1016/j.tranon.2020.100978 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review article
Bárcenas-López, Diego Alberto
Mendiola-Soto, Diana Karen
Núñez-Enríquez, Juan Carlos
Mejía-Aranguré, Juan Manuel
Hidalgo-Miranda, Alfredo
Jiménez-Morales, Silvia
Promising genes and variants to reduce chemotherapy adverse effects in acute lymphoblastic leukemia
title Promising genes and variants to reduce chemotherapy adverse effects in acute lymphoblastic leukemia
title_full Promising genes and variants to reduce chemotherapy adverse effects in acute lymphoblastic leukemia
title_fullStr Promising genes and variants to reduce chemotherapy adverse effects in acute lymphoblastic leukemia
title_full_unstemmed Promising genes and variants to reduce chemotherapy adverse effects in acute lymphoblastic leukemia
title_short Promising genes and variants to reduce chemotherapy adverse effects in acute lymphoblastic leukemia
title_sort promising genes and variants to reduce chemotherapy adverse effects in acute lymphoblastic leukemia
topic Review article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720095/
https://www.ncbi.nlm.nih.gov/pubmed/33290991
http://dx.doi.org/10.1016/j.tranon.2020.100978
work_keys_str_mv AT barcenaslopezdiegoalberto promisinggenesandvariantstoreducechemotherapyadverseeffectsinacutelymphoblasticleukemia
AT mendiolasotodianakaren promisinggenesandvariantstoreducechemotherapyadverseeffectsinacutelymphoblasticleukemia
AT nunezenriquezjuancarlos promisinggenesandvariantstoreducechemotherapyadverseeffectsinacutelymphoblasticleukemia
AT mejiaarangurejuanmanuel promisinggenesandvariantstoreducechemotherapyadverseeffectsinacutelymphoblasticleukemia
AT hidalgomirandaalfredo promisinggenesandvariantstoreducechemotherapyadverseeffectsinacutelymphoblasticleukemia
AT jimenezmoralessilvia promisinggenesandvariantstoreducechemotherapyadverseeffectsinacutelymphoblasticleukemia